Prurigo Nodularis Treatment Market - By Product (Antihistamines, Capsaicin Cream, Corticosteroids, Emollients), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies) & Forecast, 2023-2032

Prurigo Nodularis Treatment Market Size

Prurigo Nodularis Treatment Market size crossed USD 2 billion in 2022 and is slated to depict a 4% CAGR from 2023 to 2032.
 

The consistent expansion of the pharmaceutical and biotechnology industry globally is among the leading factors spurring the demand for prurigo nodularis treatment. The consistently expanding geriatric population base and the subsequent rise in the burden of chronic diseases have encouraged pharmaceutical manufacturers worldwide to make significant R&D investments and develop novel antibiotics, treatments, and vaccines.
 

Besides, the ongoing advancements focused on fulfilling the healthcare requirements of people living in emerging economies are likely to offer an anticipated boost to the pharmaceutical sector.
 

Limited treatment options may restrict industry progress

Prurigo nodularis is an underdiagnosed disease requiring an extensive range of topical steroids to contain the spread of the disease. However, at present, only a limited number of target therapies are available in the market to treat the condition. Therefore, the lack of approved drugs or targeted therapies may restrict industry expansion.
 

Prurigo Nodularis Treatment Market Analysis

Prurigo nodularis treatment market from the corticosteroids segment is set to amass more than 35.5% business share by 2032. The increasing usage of corticosteroids in the treatment of the given health condition will primarily support segment landscape. Drugs containing corticosteroids help lower bodily inflammation and minimize the occurrence of itching, swelling, and redness. Given these exceptional attributes, corticosteroids are considered a preferred treatment choice for patients with prurigo nodularis, which will drive segmental revenues.
 

Prurigo nodularis treatment market from the prurigo nodularis treatment industry segregates into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment garnered over USD 800 million in 2022. The increasing prevalence of prurigo nodularis has resulted in an elevated demand for a variety of medications, ointments, lotions, and other goods associated with the disease treatment. Retail stores are easily accessible and offer a range of these medications at affordable prices, which may bolster their sales in the foreseeable future.
 

North America prurigo nodularis treatment market held a substantial revenue share over 40% in 2022, backed by the consistent expansion of the aging populace. For instance, the elderly population globally is estimated to grow double fold and cross 1.5 billion by 2050. The greater susceptibility of the elderly to several illnesses may result in increased incidences of prurigo nodularis, which will boost product adoption across North America.
 

Prurigo Nodularis Treatment Market Share

Major firms having a strong presence in the prurigo nodularis market are:

• Teva Pharmaceutical Industries Ltd
• Pfizer Inc
• Sanofi
• GlaxoSmithKline plc
• Merck & Co Inc
• Bayer AG
• Johnson & Johnson Services Inc
• Galderma Takeda Pharmaceuticals

Companies operating in this vertical are emphasizing developing novel treatment options for patients suffering from the given skin condition and making a mark in the healthcare sector.
 

Impact of COVID-19 Pandemic

The onset of the global health calamity COVID-19 disrupted industry value chains across the globe and took a huge toll on the global healthcare sector. However, the prurigo nodularis treatment industry stayed quite unaffected by the disruption caused during the crisis. The disease is an autoimmune disorder, and only a few patients witnessed elevated symptoms due to the viral outbreak. Additionally, market players, governments, and non-government organizations across several economies undertook necessary initiatives to generate disease awareness and introduce novel preventive and target therapies and treatments, further expanding the market share.
 

The Prurigo nodularis treatment market report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

By Product

• Antihistamines
• Capsaicin Cream
• Corticosteroids
• Emollients
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Others
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • Others